POET Technologies Recaps Highlights of CEO’s Update on Commercial Activities and Provides Results of 2026 AGM

POET reported AGM results with shareholders approving the director slate (all candidates received ≥94.35% of votes) and the auditor appointment (Davidson & Company LLP approved with ~97%). Operationally, management reiterated its production ramp is on schedule for 2H 2026, targeting volume shipments of optical engines, and plans to scale capacity to up to 1M units/month by end-2027 (>10x current capacity). Following $830M raised in equity over the past 12 months (potential additional $661M via warrants), the company plans to deploy ~$50M for capital equipment in 2H 2026 and highlighted >$100M expected annual revenue across 10+ customer engagements, including a ramped 800G optical engine order and a major NRE agreement for External Light Source (ELS) applications.

Analysis

The real market signal is not the long-dated revenue rhetoric; it’s that POET now has enough capital to de-risk supplier negotiations and pre-buy strategic optionality. That can matter in a constrained AI optics supply chain because the scarce assets are not just wafers, but qualified packaging, test capacity, and customer-approved process windows. If POET can lock those down, the second-order winner is its contract manufacturing and component ecosystem; the loser is any smaller photonics entrant forced to compete for the same bottlenecks with a weaker balance sheet.

That said, the equity overhang is still the biggest valuation drag. The company has effectively funded an execution story years ahead of cash flow, so the stock will trade less on narrative and more on conversion metrics: shipped units, yield, gross margin, and customer pull-through. Until there is visible evidence of repeatable volume orders, the market should treat capacity targets as call options on a future TAM, not as present earnings power; that caps upside in the near term even if sentiment stays constructive.

Contrarian view: the consensus may be underestimating how hard it is to move from lab-grade wins to high-volume photonics economics. The failure mode is not demand — it is qualification slippage, installation delays, or customer redesigns that push meaningful revenue out by 2-4 quarters. If H2 2026 shipments do not show up in filings or if the first gross margin prints do not expand sequentially, the stock likely reprices as a financing story rather than an AI infrastructure winner.

Key Decisions for Investors

• No aggressive chase here: wait for first evidence of volume shipments or booked revenue in filings before underwriting the 2026 ramp; until then, treat POET as a high-beta watchlist name rather than a core long.
• If already long POET, use strength to trim into any post-PR pop; the dilution overhang from past equity issuance and warrant capacity should cap multiple expansion until revenue converts.
• For relative value, consider a cautious long POET / short a basket of cash-generative optics incumbents only after POET prints tangible shipment data; before that, the pair is premature because the short thesis is not yet grounded in operating proof.
• Set an alert on the next quarterly gross margin and inventory build: a failure to show sequential margin improvement or meaningful customer deposits would falsify the ramp thesis and likely trigger a de-rating.
• Watch for any delay to H2 2026 shipment start or 2028 scale timing; a single quarter slip would matter more than headline capacity, because execution timing is the main driver of valuation from here.